News
News
 |
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 27, 2022- The new collaboration expands upon two successful partnered studies concluded in the recent year
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, announced today the initiation of the third stage of a collaborative...
-
Jan 4, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company's Phase IIa...
-
Dec 21, 2021- Upon closing its IPO the company appointed four new board members. Dr. Ferenc Tracik joined the company's senior management as Chief Scientific Officer.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the...
-
Dec 13, 2021
NeuroSense Therapeutics Ltd., (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating...
-
Dec 8, 2021
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as...
